Harvard Bioscience Return on Equity

Harvard Bioscience (HBIO) currently reports a ROE of -97.39%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Harvard Bioscience's ROE history and peer comparisons.

Harvard Bioscience's ROE of -97.39% is lower than the Healthcare sector average of 29.33%. That is roughly 432.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Harvard Bioscience's current -97.39% should be judged against Healthcare norms (sector average: 29.33%) and against HBIO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -97.39%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Harvard Bioscience, and consider following HBIO for alerts when major investors trade the stock.

Harvard Bioscience is classified in the Healthcare sector. On ROE, it currently shows -97.39% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HBIO with unrelated industries.